Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease

These plasma pTau biomarkers that are less costly and easier to obtain, may provide appropriate reliability as a predictor of clinical outcomes, similar to amyloid PET. Plasma pTau biomarkers also have a greater standard effect size than clinical outcomes and are more sensitive in predicting disease progression. Therefore, plasma pTau biomarkers could support early phase clinical trials with smaller sample sizes than clinical outcomes, using a more accessible and cost-effective biomarker.